SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A cartoon of a scientist standing in a laboratory, next to a microscope and flasks
Government
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts
In an open letter addressing the Trump administration’s proposed budget cuts to HHS, the executives urged Congress to continue “robust federal funding” for scientific research, which they say will help maintain U.S. biotech leadership globally.
June 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Influenza
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
June 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of employer’s hand holding employee who was laid off to drop him out of office
Layoffs
Sage Sacks Entire Staff After Supernus Buyout
As of Apr. 22, Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks after Maryland’s Supernus Pharmaceuticals acquired Sage for up to $795 million.
June 30, 2025
 · 
1 min read
 · 
Tristan Manalac
FDA
FDA’s AI Rollout Raises Questions Around Readiness, Legality
The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside experts.
June 30, 2025
 · 
6 min read
 · 
Natalia Mesa
Human hand holds brilliant stone. Big gold Diamond in the arm.Concept of good creative idea or business insight, secret or dream. Vector illustration
Rare diseases
Ultrarare Therapies Could Be Reality with Advances in Tech, Delivery and Regulation
Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ultrarare disease treatments possible.
June 30, 2025
 · 
6 min read
 · 
Dan Samorodnitsky
Facade of the FDA's office in Maryland
Approvals
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past month.
June 30, 2025
 · 
9 min read
 · 
Tristan Manalac
Themis with sword and scales in cyberspace. Ai regulation, artificial intelligence and law issues concept. Vector illustration.
Legal
Supreme Court Leaves PrEP Drug Coverage Decisions to RFK’s Task Force
The high court found that members of a task force that determines what preventive drugs must be covered can be removed at will by HHS Secretary Robert F. Kennedy Jr.
June 27, 2025
 · 
2 min read
 · 
Annalee Armstrong
Vaccines
ACIP Skips Votes on COVID and Moderna’s mRESVIA but Scrutinzes mRNA Vaccine Safety
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to Truist Securities analysts. Meanwhile, the FDA moves forward on having Pfizer/BioNTech and Moderna update labels for their COVID vaccines.
June 27, 2025
 · 
2 min read
 · 
Jef Akst
Wooden blocks with arrow and error icon. Delays and disruptions, stop the process, critical error concept
Neurodegenerative disease
Edgewise Takes a Hit as FDA Blocks Accelerated Path for Becker Muscular Dystrophy Drug
The FDA found that data from a single Phase II study were “insufficient” to justify an accelerated approval review for sevasemten in Becker muscular dystrophy.
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS